Loading
A phase 2 trial of Eltrombopag in Acute myeloid leukaemia, run by French Innovative Leukemia Organisation, active and no longer recruiting.
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy is a phase 2 interventional study registered as NCT03603795 by French Innovative Leukemia Organisation, with 110 participants planned, started 2018-10-11 and due to reach its primary completion in 2022-06-15. Interventions recorded: Eltrombopag, Placebo. Conditions recorded: Acute Myeloid Leukemia.
Linked to the drug Eltrombopag because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Eltrombopag and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Eltrombopag and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia and the tag pipeline.